Role of abatacept in the management of rheumatoid arthritis
References (35)
- et al.
Covalent dimerization of CD28/ CTLA-4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions
J Biol Chem
(1996) - et al.
Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors
Immunity
(1994) Guidelines for the management of rheumatoid arthritis: 2002 Update
Arthritis Rheum
(2002)Arthritis prevalence rising as baby boomers grow older
(2006)Economic burden of rheumatoid arthritis: A systematic review
Rheumatology (Oxford)
(2000)- et al.
An assessment of the annual and longterm direct costs: The impact of poor function and functional decline
Arthritis Rheum
(1999) - et al.
Rheumatoid arthritis: An overview of new and emerging therapies
J Clin Pharmacol
(2005) Medical Subject Headings
(2006)- et al.
Costimulatory blockade in patients with rheumatoid arthritis: A pilot, dose-finding, double-blind, placebocontrolled clinical trial evaluating CTLA4-Ig and LEA29Y eighty-five days after the first infusion
Arthritis Rheum
(2002) - et al.
Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig
N Engl J Med
(2003)
Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: Twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial
Arthritis Rheum
Study IM101101
Abatacept for rheumatoid arthritis refractory to tumor necro sis factor alpha inhibition
N Engl J Med
Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: A randomized trial
Ann Intern Med
Safety and patient-reported outcomes associated with abatacept in the treatment of rheumatoid arthritis patients who received background disease modifying anti-rheumatic drugs (DMARDS): The ASSURE trial. RA treatment: Biologics and gene therapy I
Complementarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1
J Exp Med
CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris
J Clin Invest
Cited by (34)
hIgD-Fc-Ig fusion protein regulates T cell functions by inhibiting TCR signaling pathway in adjuvant arthritis rats
2023, International ImmunopharmacologyUse of In silico tools for screening buffers to overcome physical instability of Abatacept
2022, Transplant ImmunologyCitation Excerpt :Also, eight tryptophan residues were located exclusively in the Fc domain and 30 tyrosine residues were distributed over both domains [12]. Abatacept, known as CTLA-4Ig; approved by the US Food and Drug Administration in December 2005 for the treatment of Rheumatoid arthritis [4,34]. The worldwide prevalence of Rheumatoid arthritis is between 0.18 and 1.07%, with an annual incidence of 0.01–0.05% [8,35].
Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412
2011, BloodCitation Excerpt :CD28 is a potential target for both inhibition and stimulation of T-cell responses. Ligand blockade with recombinant CTLA4-Ig has entered the clinic,6 and blockade of CD28 itself by mAb or mAb fragments has been successful in rodent and primate models.7-9 With regard to T-cell stimulation, mAb have been developed that activate T cells without the need to ligate the TCR, making them polyclonal T-cell activators.10-12
Immunotoxicology of Biological Response Modifiers
2010, Comprehensive Toxicology, Second EditionTargeting lymphocyte activation to treat rheumatoid arthritis
2009, Revue du Rhumatisme (Edition Francaise)Targeting lymphocyte activation to treat rheumatoid arthritis
2009, Joint Bone SpineCitation Excerpt :The proportion of patients with adverse events requiring study withdrawal was 5.5% with abatacept and 3.9% with the placebo, the serious adverse event rate was 13.6% vs. 12.3%, and mortality was 0.5% vs. 0.6%. A 2006 systematic literature review showed a small increase in the risk of infections and severe infections with abatacept compared to a placebo (infections, 54% vs. 48%; severe infections, 3% vs. 1%) [37]. A metaanalysis of the data from the phase II trials, ASSURE, AIM, and ATTAIN was therefore conducted to assess the risk of infection associated with abatacept therapy.